










<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/css" href="http://52.214.119.220/wiki/skins/common/feed.css?97"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/">
	<channel>
		<title>Group:SMART:Greenwood SMART Team - Revision history</title>
		<link>http://52.214.119.220/wiki/index.php?title=Group:SMART:Greenwood_SMART_Team&amp;action=history</link>
		<description>Revision history for this page on the wiki</description>
		<language>en</language>
		<generator>MediaWiki 1.11.2</generator>
		<lastBuildDate>Thu, 09 Apr 2026 17:33:39 GMT</lastBuildDate>
		<item>
			<title>Eran Hodis: New page: ==2008-2009 SMART Team Project: GLP-1R with Exendin== {{STRUCTURE_3c59 |  PDB=3c59  |  SCENE=  }} Image:Ourteam.jpg   Type 2 diabetes is characterized by chronically elevated blood glu...</title>
			<link>http://52.214.119.220/wiki/index.php?title=Group:SMART:Greenwood_SMART_Team&amp;diff=1224058&amp;oldid=prev</link>
			<description>&lt;p&gt;New page: ==2008-2009 SMART Team Project: GLP-1R with Exendin== {{STRUCTURE_3c59 |  PDB=3c59  |  SCENE=  }} &lt;a href=&quot;/wiki/index.php/Image:Ourteam.jpg&quot; title=&quot;Image:Ourteam.jpg&quot;&gt;Image:Ourteam.jpg&lt;/a&gt;   Type 2 diabetes is characterized by chronically elevated blood glu...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;==2008-2009 SMART Team Project: GLP-1R with Exendin==&lt;br /&gt;
{{STRUCTURE_3c59 |  PDB=3c59  |  SCENE=  }}&lt;br /&gt;
[[Image:Ourteam.jpg]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Type 2 diabetes is characterized by chronically elevated blood glucose levels resulting from impaired insulin function.  This results, in part, from low levels of the natural hormone, glucagon like peptide-1 (GLP-1).  GLP-1 binds to and activates the GLP-1 receptor (GLP-1R) resulting in increased insulin synthesis and secretion which serves to reduce blood glucose levels.  As a result, the GLP-1 receptor has become an important therapeutic target for the treatment of type 2 diabetes.  The synthetic Exendin-4 has a higher affinity for the receptor.  Due to the differences in structure, Exendin-4 has no longer duration of action, therefore releasing more insulin. An important feature of the GLP-1R is the N-terminal extracellular domain (NTD).  A two-step mechanism occurs through GLP-1 binding to the NTD and receptor activation via the core domain of the receptor.  In the first step of binding, hydrogen bonds are formed between the NTD and Exendin-4.  By understanding the nature of GLP-1R activation, therapeutic drugs could be developed to stimulate insulin production. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;scene name='Becky_Kehler/Greenwood_SMART_Team/Glp1r_binding/1'&amp;gt;Key residues responsible for binding exendin.&amp;lt;/scene&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[[Image:Glp1rviewa.jpg]][[Image:Glp1rviewb.jpg]]&lt;/div&gt;</description>
			<pubDate>Sat, 02 Apr 2011 21:25:16 GMT</pubDate>			<dc:creator>Eran Hodis</dc:creator>			<comments>http://52.214.119.220/wiki/index.php/Group_talk:SMART:Greenwood_SMART_Team</comments>		</item>
	</channel>
</rss>